Updated on 14 September 2026
MetaTool: Strategic Investment in Pharma Evidence Intelligence
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
About
FRESCI is developing MetaTool to help biomedical teams connect fragmented evidence, identify gaps and preserve scientific reasoning across development decisions.
The concept builds on our peer-reviewed research in the Journal of Translational Medicine. It proposes AI-supported integration of existing assessment methods, keeping sources, assumptions and uncertainty traceable for expert review.
Potential applications include model selection, preclinical programme assessment and preparation for first-in-human decision-making.
We welcome discussions on financing proof-of-concept development, evaluation with industry partners and commercialisation research, alongside a planned EIC Pathfinder proposal. Investment scope and terms would be defined around agreed milestones, ownership and evidence of customer demand.
Stage
- Pre-seed funding | Idea validation
Organisation
Similar opportunities
Project cooperation
MetaTool: AI for Translational Evidence Integration — EIC Pathfinder Partners
- Technical
- Strategic Partnership
- Completing the consortia
- Consortium seeks Partners
- Drafting - writing the project proposal
Marco Straccia
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Expertise
NAM Evidence, Regulatory Science and Translational Strategy
Marco Straccia
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Service
NAM and MedTech Strategy, Biomedical Business Support and Project Delivery
- Other
- Marketing
- Consulting
- Technology Transfer
- Innovation management
- Research & Development
- Supply chain management
- Education, Training & Qualifying
Marco Straccia
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain